RxDoctor Payments Data

Manuel Figueroa, MD

General Practice · Los Angeles, CANPI 1770679102

Payments from drug & device makers

$1,717in general payments, 2019–2025

Across 71 payments — averaging $24.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$248
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$179
  • Bayer$177
  • Biotronik Inc.$138
  • AbbVie$134
  • Boehringer Ingelheim$125
  • plus $717 from 16 others

What the payments were for

  • Speaking & faculty fees$593%
  • Food & beverage$1,63195%
  • Education$272%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,717 in reported general payments places this provider in the 85th percentile of 12,963 general practice providers in California.

See all general practice providers in California

Medicare billing

Part B allowed, 2024
$42,380
Medicare patients
107
Services billed
610

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
KerendiaFinerenone124$105,294
JanuviaSitagliptin Phosphate109$93,774
FarxigaDapagliflozin Propanediol74$76,741
EliquisApixaban54$51,981
MyrbetriqMirabegron54$48,151
GemtesaVibegron25$30,449
TradjentaLinagliptin41$30,185
OzempicSemaglutide27$29,417
JardianceEmpagliflozin25$20,245
TrulicityDulaglutide15$18,689
Lantus SolostarInsulin Glargine,hum.Rec.Anlog91$15,941
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$13,756
Glipizide-MetforminGlipizide/Metformin Hcl104$12,238
LinzessLinaclotide16$11,506
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14$7,894

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BayerKerendia$177$105,294124 claims
AstraZenecaFarxiga$66$76,74174 claims
Boehringer IngelheimTradjenta, Jardiance, Combivent Respimat$125$55,72377 claims
PfizerEliquis$248$51,98154 claims
Astellas Pharma US IncMyrbetriq$48$48,15154 claims
Sumitomo Pharma America, Inc.Gemtesa$26$30,44925 claims
Novo NordiskOzempic$98$29,41727 claims
Lilly USA, LLCTrulicity$56$18,68915 claims
GSKTrelegy Ellipta, Breo Ellipta$41$18,16034 claims
AbbVieLinzess$134$11,50616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 12,963 general practice providers in California.

Other general practice in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →